FRG Family Wealth Advisors LLC Increases Position in Becton, Dickinson and Company (NYSE:BDX)

FRG Family Wealth Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.8% in the second quarter, HoldingsChannel reports. The firm owned 14,577 shares of the medical instruments supplier’s stock after buying an additional 795 shares during the period. FRG Family Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $3,433,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Dorsey & Whitney Trust CO LLC lifted its position in Becton, Dickinson and Company by 44.7% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 3,582 shares of the medical instruments supplier’s stock valued at $837,000 after acquiring an additional 1,107 shares during the last quarter. Global X Japan Co. Ltd. lifted its holdings in shares of Becton, Dickinson and Company by 2.7% during the 2nd quarter. Global X Japan Co. Ltd. now owns 1,810 shares of the medical instruments supplier’s stock valued at $423,000 after purchasing an additional 48 shares during the last quarter. Choreo LLC boosted its position in shares of Becton, Dickinson and Company by 414.3% in the 2nd quarter. Choreo LLC now owns 5,138 shares of the medical instruments supplier’s stock worth $1,180,000 after purchasing an additional 4,139 shares in the last quarter. Wedbush Securities Inc. grew its stake in Becton, Dickinson and Company by 17.1% during the 2nd quarter. Wedbush Securities Inc. now owns 8,952 shares of the medical instruments supplier’s stock worth $2,092,000 after buying an additional 1,308 shares during the last quarter. Finally, PFG Investments LLC increased its position in Becton, Dickinson and Company by 73.2% during the 2nd quarter. PFG Investments LLC now owns 1,824 shares of the medical instruments supplier’s stock valued at $426,000 after buying an additional 771 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 2.4 %

Shares of NYSE:BDX opened at $237.22 on Tuesday. The business’s 50 day moving average price is $234.22 and its 200-day moving average price is $235.82. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The firm has a market capitalization of $68.57 billion, a price-to-earnings ratio of 52.25, a price-to-earnings-growth ratio of 1.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the business posted $2.96 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Analyst Ratings Changes

BDX has been the subject of several recent analyst reports. Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Raymond James cut their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup decreased their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target for the company. Finally, Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.